Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (14844)	2/26/1999 1:01:00 PM
From: timers	Read Replies (4) \| Respond to of 122087

I was on your pick fast (PCOR)but by the time my broker checked for shares and came back, it was where it is now. 51-ish. Do you already have the shares lined up with your broker, or do they have basically anything you want - in a heartbeat? Also, what put them on your radar, because I need to do something if I'm to have a chance. I'm quick as s*&t on the phone, but if my brkr. takes a minute, it's all over on the quick ones.

To: Anthony@Pacific who wrote (14844)	2/26/1999 1:05:00 PM
From: AS Hibbs	Respond to of 122087

The presentation is on Monday, March 22, 1999, at the 9th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in Berlin, Germany. Scott

To: Anthony@Pacific who wrote (14844)	2/26/1999 1:08:00 PM
From: Doorman	Respond to of 122087

Final Phase 2 to be released later this year. The current data is preliminary but impressive... Here's a capsule summary of release: NeXstar Pharmaceuticals, Inc. (Nasdaq/NMS:NXTR - news) today announced that new Phase II data for its proprietary investigational antibiotic MiKasome (liposomal amikacin) has been accepted for presentation on Monday, March 22, 1999, at the 9th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in Berlin, Germany. The lead investigator for the clinical study, Dr. John Krieger, will focus on preliminary Phase II data in patients with complicated urinary tract infections (UTI). Final results are expected to be released later this year. ''These patients had urinary tract infections that were complicated by anatomic and functional disorders,'' Krieger said. ''Examples of these include: diabetic bladder problems, chronic bladder catheters, and bladder stones or prostate disease.'' ''The study protocol evaluated four MiKasome dosing regimens,'' Krieger said. ''The results of the single, fixed-dose regimens were especially encouraging. High clinical and microbiologic cure rates following single-dose therapy may offer particular benefit to physicians and patients alike.''